Survival rate

EQS-News: Defence Therapeutics Inc.: DELIVERY OF ENCAPSULATED ACCUTOXTM-CHITOSAN NANOPARTICLES TRIGGERS COMPLETE TUMOR REGRESSION IN ANIMALS WITH PRE-ESTABSLIHED SOLID LYMPHOMA

Retrieved on: 
Tuesday, October 17, 2023
Survival rate, Antibody, Bandage, Bleeding, Animal, Therapy, Molecular medicine, Growth, Neoplasm, Injection, Skin, Vaccine, Defense, Chitosan

The formulation was delivered twice with a 2 weeks interval and treated animals were followed for up to 40 days.

Key Points: 
  • The formulation was delivered twice with a 2 weeks interval and treated animals were followed for up to 40 days.
  • The tumors in animals treated with AccuTOXTM-Chitosan injections along with anti-PD-1 co-administration regressed and exhibited a prolonged survival rate.
  • The Defence team was able to bypass this limitation by encapsulating it into chitosan-based nanoparticles.
  • In addition to its agricultur al and industrial applications, chitosan is often useful in bandages to reduce bleeding and as an antibacterial agent.

Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

Retrieved on: 
Wednesday, October 11, 2023
Acromegaly, MBA, NYSE, Acquisition, FOLFIRINOX, Pancreas, PK, Carcinoid syndrome, Safety, Survival, Therapy, Oncolytics Biotech, JV, NEO, ADC, Research, JD, Lung cancer, Patient, Ovarian cancer, CR, PFE, Genelux Corporation, Survival rate, TSX, VC, Public, Medicine, Cancer, FDA, Melanoma, Immunotherapy, Pancreatic Cancer Action Network, FTD, Diagnosis, Glomus tumor, News, Death, ORR, PDAC, IND, ONC, CAD, Growth, Pancreatic cancer, Pharmaceutical industry, Medical imaging, Seagen, Pfizer, Pelareorep

VANCOUVER, British Columbia, Oct. 11, 2023 /PRNewswire/ -- USA News Group - Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer from 1990 to 2019. And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates. However, with strategies such as the "Cancer Moonshot," a $200M boost from a newly formed VC firm, and sustained efforts from the Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer organization, which this year noted the 5-year survival rate is approximately 12%. Many new developments are currently underway from biotech firms searching for new treatments and methods of diagnosis, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Genelux Corporation (NASDAQ: GNLX), Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), Pfizer Inc. (NYSE: PFE) and Seagen Inc. (NASDAQ: SGEN).

Key Points: 
  • And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates.
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • Further survival follow up is required to inform our next steps in pancreatic cancer," said Roger Dansey, M.D., Chief Medical Officer at Seagen.
  • "We are continuing to advance the ongoing phase 2 trial of SEA-CD40 in melanoma and in non-small cell lung cancer."

Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

Retrieved on: 
Wednesday, October 11, 2023
Acromegaly, MBA, NYSE, Acquisition, FOLFIRINOX, Pancreas, PK, Carcinoid syndrome, Safety, Survival, Therapy, Oncolytics Biotech, JV, NEO, ADC, Research, JD, Lung cancer, Patient, Ovarian cancer, CR, PFE, Genelux Corporation, Survival rate, TSX, VC, Public, Medicine, Cancer, FDA, Melanoma, Immunotherapy, Pancreatic Cancer Action Network, FTD, Diagnosis, Glomus tumor, News, Death, ORR, PDAC, IND, ONC, CAD, Growth, Pancreatic cancer, Pharmaceutical industry, Medical imaging, Seagen, Pfizer, Pelareorep

VANCOUVER, British Columbia, Oct. 11, 2023 /PRNewswire/ -- USA News Group - Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer from 1990 to 2019. And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates. However, with strategies such as the "Cancer Moonshot," a $200M boost from a newly formed VC firm, and sustained efforts from the Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer organization, which this year noted the 5-year survival rate is approximately 12%. Many new developments are currently underway from biotech firms searching for new treatments and methods of diagnosis, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Genelux Corporation (NASDAQ: GNLX), Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), Pfizer Inc. (NYSE: PFE) and Seagen Inc. (NASDAQ: SGEN).

Key Points: 
  • And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates.
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • Further survival follow up is required to inform our next steps in pancreatic cancer," said Roger Dansey, M.D., Chief Medical Officer at Seagen.
  • "We are continuing to advance the ongoing phase 2 trial of SEA-CD40 in melanoma and in non-small cell lung cancer."

A pep in their step: Local school district makes strides for kids everywhere at St. Jude Walk/Run Memphis

Retrieved on: 
Tuesday, October 3, 2023
Children, Primary, Secondary, Education, Health, Philanthropy, Oncology, Other Philanthropy, Hospitals, Foundation, Consumer, Continuing, Survival rate, Travel, Housing, Food, Life, NCI-designated Cancer Center, Walkers, ALSAC, Foot, Cancer, Hope, National Cancer Institute (Egypt), Research, Multimedia, National Cancer Institute, School, Student, Child, Love, Young Lives vs Cancer, Walk Run Cha-Cha, Hospital, Tom Lee Park, Jude the Apostle

View the full release here: https://www.businesswire.com/news/home/20231003922202/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231003922202/en/
    Staff from A. Maceo Walker Middle School smile prior to the 2023 St. Jude Walk/Run Memphis.
  • (Photo: Business Wire)
    Among those communities were 10 teams of students, staff and school leaders from across the Memphis-Shelby County Schools District, the largest public school district in Tennessee.
  • Visit St. Jude Inspire to discover powerful St. Jude stories of hope, strength, love and kindness.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

Grant Thornton names MBC Travelers as its new Purple Paladin

Retrieved on: 
Tuesday, October 3, 2023
Finance, Consulting, Fintech, Accounting, Professional Services, Philanthropy, Other Philanthropy, Foundation, Asset Management, Dignity, Survival rate, Volunteering, Survivor, Grant Thornton International, Soldier, Life, Homelessness, Education, Hair loss, Dog, COVID-19, Rosie Jones (comedian), Hope, Woman, Prescription, Research, Veteran, Down syndrome, Literature, Student, Hospital, The Forum of Culture and Arts of Uzbekistan Foundation (The Fund Forum), MBC, Breast cancer, Intellectual, Refugee, Museum, Spectrum, Box, Purple, Diagnosis, Immunodeficiency, Hunger, Book, Disease, Management, Medical imaging, Tourism, Entertainment, Residential care, Interior design, Nursing, Tutoring, GroupMe

MBC Travelers was founded in 2021 by Jennifer Pace, who has been living with metastatic breast cancer (MBC) for over a decade.

Key Points: 
  • MBC Travelers was founded in 2021 by Jennifer Pace, who has been living with metastatic breast cancer (MBC) for over a decade.
  • “We’re there for each other through the good and the bad, from the beginning to the end.”
    To learn more about MBC Travelers, visit https://www.mbctravelers.com/
    MBC Travelers joins 16 other 501(c)(3) nonprofits that Grant Thornton previously selected as Purple Paladins.
  • Grant Thornton’s Purple Paladins program derives its name from the word paladin, a champion of a cause.
  • Grant Thornton and its professionals have donated more than $1 million to Purple Paladin nonprofits, and more than 650 Grant Thornton professionals have volunteered their time and skills to support to the firm’s Purple Paladins.

BPGbio Announces Promising Readout from Phase 2a Trial Evaluating BPM 31510 IV for Pancreatic Cancer

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Technology, Clinical Trials, Artificial Intelligence, Biotechnology, Pancreatic cancer, Survival rate, Coronavirus Scientific Advisory Board, Phosphorylation, Family, Biomarker, Advisory board, BPM, Patient, Division, Cancer, TME, Diagnosis, Rare, Death, Neurology, Tumor microenvironment, Pharmaceutical industry, Medical imaging

BPGbio, Inc. , a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that review of the Phase 2a trial in advanced, refractory pancreatic cancer patients by a Medical Advisory Board for its BPM 31510IV for Pancreatic Cancer recommends advancing the asset into a Phase 2b trial following a comprehensive analysis of data observed from a Phase 1 and completed Phase 2a clinical studies.

Key Points: 
  • BPGbio, Inc. , a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that review of the Phase 2a trial in advanced, refractory pancreatic cancer patients by a Medical Advisory Board for its BPM 31510IV for Pancreatic Cancer recommends advancing the asset into a Phase 2b trial following a comprehensive analysis of data observed from a Phase 1 and completed Phase 2a clinical studies.
  • As a result, the Advisory Board recommends the drug candidate be further assessed as a potential first-line therapy in advanced pancreatic cancer patients in the Phase 2b trial design.
  • In the Phase 2a clinical trial, BPM 31510 IV demonstrated a tolerable safety profile in advanced refractory pancreatic cancer patients with an early indication for potential clinical benefit.
  • Project Survival® has been supported by the Alliance for Families Fighting Pancreatic Cancer (AFFPC).

Domino's® Celebrates the Opening of Newest Housing Facility at St. Jude Children's Research Hospital®: The Domino's Village

Retrieved on: 
Thursday, September 28, 2023
Yoga, Survival rate, Village, Housing, Domino's Pizza, Inc. v. McDonald, Life, Friends, ANN, ALSAC, Cancer, St. Jude Children's Research Hospital, Dining room, Skyway, Domino's, Patient, North Third Street Historic District (Louisiana, Missouri), Meditation, Hospital, Table, Family, NYSE, Common, Fast food, General store, Hotel, Jude the Apostle, Dominoes

ANN ARBOR, Mich., Sept. 28, 2023 /PRNewswire/ -- Domino's Pizza Inc. (NYSE: DPZ), the largest pizza company in the world, is proud to announce the grand opening of The Domino's Village: the newest St. Jude Children's Research Hospital housing facility, located on its campus in Memphis, Tennessee.

Key Points: 
  • Domino's is proud to announce the grand opening of The Domino's Village: the newest St. Jude housing facility.
  • "We could not be any more excited to celebrate St. Jude's newest housing facility for patient families," said Russell Weiner, Domino's CEO.
  • The Domino's Village is one of four housing facilities available to St. Jude patients and it is the first to accommodate both short- and long-term stays.
  • Thanks to support from Domino's stores and customers, St. Jude will not stop until no child dies from cancer.

Art Meets Athletics in Celebration of African American Achievement at St. Jude Spirit of the Dream

Retrieved on: 
Tuesday, September 26, 2023
Other Health, Other Philanthropy, Parenting, Children, Oncology, Family, Hospitals, Fund Raising, Consumer, Foundation, Arts, Museums, Philanthropy, Entertainment, General Health, Basketball, People with Disabilities, Sports, Health, Survival rate, Apple Music, Bell, Travel, Housing, Food, Djed, Life, National Basketball Association, St. Joseph's Hospital, Dream, NCI-designated Cancer Center, ALSAC, Cancer, African, National Cancer Institute (Egypt), Hope, Multimedia, History, Language, National Cancer Institute, IHeartRadio, NBA, Child, Love, Hospital, African Americans, Nightclub, Toy, Nursing, Memphis Grizzlies, Jude the Apostle

Later in life, he created and auctioned an original work of art with all proceeds donated to St. Jude.

Key Points: 
  • Later in life, he created and auctioned an original work of art with all proceeds donated to St. Jude.
  • "When I think about honoring the dream of St. Jude founder Danny Thomas, I think about his spirit of belief and faith,” said Fordjour.
  • St. Jude Spirit of the Dream celebrates the achievements of African Americans who have made significant contributions to Memphis and beyond while embodying the spirit of the St. Jude mission.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138

Retrieved on: 
Monday, September 25, 2023
Survival rate, Real-time, Therapy, GBM, Neoplasm, Clinical trial, Cancer, Pharmacokinetics, Transcoding, Prognosis, RNA, Brain, Glioblastoma, MRI, Professor, Magnetic resonance imaging, Patient, Michigan State University, Mouse, TTX, Disease, Pharmaceutical industry, Medical imaging

BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX-MC138, in murine models bearing human glioblastoma multiforme (GBM) tumors.

Key Points: 
  • BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therapeutic candidate, TTX-MC138, in murine models bearing human glioblastoma multiforme (GBM) tumors.
  • In this study, the therapeutic candidate was delivered to brain tumors and effectively engaged its target.
  • In addition, the pharmacodynamic activity of TTX-MC138 was determined by measuring inhibition of the therapeutic target, miRNA-10b, using qRT-PCR.
  • Importantly, the therapeutic candidate showed lasting activity and significantly inhibited miRNA-10b, known to be a driver of tumor progression in glioblastoma.

THE ROYAL COMMISSION FOR ALULA TO HIGHLIGHT SUCCESSES IN REVITALISING ARID ENVIRONMENTS TO GLOBAL AUDIENCE AT SOCIETY FOR ECOLOGICAL RESTORATION CONFERENCE IN DARWIN, AUSTRALIA

Retrieved on: 
Tuesday, September 19, 2023
Survival rate, UNESCO, Society, IUCN, Rejuvenation, Royal Commission for Al-'Ula, Culture, RCU, Policy, Seedling, Hope, Acacia, Hegra, Natural heritage, Society for Ecological Restoration, Regeneration, Royal commission, International Union for Conservation of Nature, World Conference, World Conference on Disaster Risk Reduction, SER, Environment, Restoration ecology, Conference, Forestry, Tourism, Al-'Ula

As the custodian of AlUla, a region with a unique ecological footprint, RCU is spearheading responsible and sustainable development at a pivotal moment for global biodiversity.

Key Points: 
  • As the custodian of AlUla, a region with a unique ecological footprint, RCU is spearheading responsible and sustainable development at a pivotal moment for global biodiversity.
  • By 2035, RCU plans to deliver the ecological restoration of at least 65,000 hectares.
  • Within AlUla's Sharaan Nature Reserve, which covers an area of 1,200 sq km, a 100-hectare restoration pilot site has become a hallmark of RCU's ecological restoration strategy.
  • SER2023 will allow RCU to communicate its overarching agenda of positioning AlUla as a pioneering model for eco-restoration.